INO (Inovio Pharmaceuticals, Inc.) שווי מצרפי של נכסים

Inovio Pharmaceuticals (INO) is targeting the global expansion of DNA technologies to combat cancer and viruses, as evidenced by the total asset price chart on GURU.Markets, which serves as a validation of the market valuation and currently stands at 58.82. Its pioneer status in immunotherapy provides the brand with global recognition. The company is currently finalizing the development of a unique drug for respiratory papillomatosis, approaching the stage of full-scale commercial sales.

Institutional capital assesses Inovio Pharmaceuticals (INO) through the lens of resource preservation amid a lack of stable revenue. This metric, calculated inversely via ROA, determines the company's total assets and liabilities. This chart of total assets reveals the rate of base degradation during the period of vaccine approval delays. The contraction of this foundation, coupled with a high cash burn rate, signals a critical decline in the asset's reliability.